Sugi Predict

Sugi Predict / Compounds / SCHEMBL3533847

SCHEMBL3533847

SCHEMBL3533847

CS(=O)(=O)OCC1CCN(C(=O)O)CC1

nearest known ligand 0.35

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ GPR119 Q8TDV5 7/20 0.35
▸ TP53 P04637 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3717160 0.90 RBP4 (0.36) ALDH1A1L3MBTL1GPR119TP53MEN1
SCHEMBL12503814 0.90 RBP4 (0.36) ALDH1A1L3MBTL1GPR119TP53MEN1
SCHEMBL18641574 0.90 RBP4 (0.36) ALDH1A1L3MBTL1GPR119TP53MEN1
SCHEMBL3321087 0.86 F10 (0.40) ALDH1A1L3MBTL1GPR119TDP1MEN1
SCHEMBL15512262 0.85 KDM4E (0.41) ALDH1A1TP53TDP1MEN1POLB
SCHEMBL13735368 0.85 KDM4E (0.41) ALDH1A1TP53TDP1MEN1POLB
SCHEMBL458216 0.83 GPR119 (0.38) ALDH1A1GPR119ATM
SCHEMBL30741144 0.83 BRD4 (0.43) L3MBTL1GPR119TP53ATM
SCHEMBL22557067 0.83 EPHX2 (0.42) ALDH1A1ATM
SCHEMBL3061976 0.82 KDM4E (0.31) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3837263-B1 NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN LA ROCHE (CH) 2024-07-03 — — EP disclosed
WO-2024112119-A1 DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 이노큐어테라퓨틱스 2024-05-30 — — WO disclosed
US-20240150373-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2024-05-09 — — US disclosed
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 — — EP disclosed
WO-2023215906-A1 KRAS G12D PROTEOLYSIS TARGETING CHIMERAS HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) 2023-11-09 — — WO disclosed
US-11802133-B2 Heterocyclic compounds as monoacylglycerol lipase inhibitors HOFFMANN-LA ROCHE INC. (US) 2023-10-31 — — US disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 — — US disclosed
US-20230050901-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-02-16 — — US disclosed
US-20230022917-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE ISTESSO THERAPEUTICS LIMITED (GB) 2023-01-26 — — US disclosed
US-20220315556-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-10-06 — — US disclosed
EP-1907384-A2 GPCR AGONISTS Prosidion Limited (GB) 2008-04-09 — — EP disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 — — EP disclosed
CN-1989119-A New benzoyl urea derivatives RICHTER GEDEON VEGYESZET (HU) 2007-06-27 — — CN disclosed
WO-2007033196-A1 MET KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-22 — — WO disclosed
US-20070060613-A1 Met kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-03-15 — — US disclosed
WO-2007003961-A2 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 — — WO disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 — — WO disclosed
EP-1043319-B1 NOVEL ALKYLAMINO DERIVATIVES MITSUBISHI CHEM CORP (JP) 2005-03-16 — — EP disclosed
EP-1043319-A1 NOVEL ALKYLAMINO DERIVATIVES MITSUBISHI CHEMICAL CORPORATION (JP) 2000-10-11 — — EP disclosed
EP-0881220-A1 DIARYLSULTAM DERIVATIVES MITSUBISHI CHEMICAL CORPORATION (JP) 1998-12-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315556-A1 FURIN INHIBITORS FURIN, TGFB1, PCSK7 ALDH1A1 3733/4885L3MBTL1 3062/4885GPR119 2318/4885
US-20240150373-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS LIPC, LPL, MGLL ALDH1A1 525/4885L3MBTL1 415/4885GPR119 53/4885
US-20230022917-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE MCL1, BCL9, BCL9L ALDH1A1 748/4885L3MBTL1 2306/4885GPR119 629/4885
US-11802133-B2 Heterocyclic compounds as monoacylglycerol lipase inhibitors LIPC, LPL, MGLL ALDH1A1 525/4885L3MBTL1 415/4885GPR119 53/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 ALDH1A1 3733/4885L3MBTL1 3062/4885GPR119 2318/4885
US-20230050901-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS LIPC, LPL, MGLL ALDH1A1 525/4885L3MBTL1 415/4885GPR119 53/4885
US-20070060613-A1 Met kinase inhibitors MET, ERBB2, ABL1 ALDH1A1 1499/4885L3MBTL1 1113/4885GPR119 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.